美利医疗系统
✦ 量化合理价值 计算方式说明
- 基于该股自身过去5年平均市盈率乘以滚动每股收益,推算出的合理价值区间为76.49-147.70。
- 当前价格比按平均倍数计算的合理价值(112.10)低20.4%。
估值 各估值倍数与自身5年区间的对比
同业对比 Medical Instruments & Supplies
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| 美利医疗系统 (MMSI) | 5.33B | 36.71 | 3.17 | 0.00% |
| Intuitive Surgical (ISRG) | 150.74B | 48.93 | 8.30 | 0.00% |
| Becton Dickinson & Co (BDX) | 52.23B | 57.93 | 2.14 | 2.19% |
| ResMed (RMD) | 33.61B | 22.91 | 5.10 | 1.00% |
| Alcon (ALC) | 31.99B | 50.52 | 1.48 | 0.53% |
| Medline (MDLN) | 31.55B | 68.24 | 2.73 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价低于晨星合理价值估算11.1%。
合理价值
Merit Medical Systems Inc is assigned a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 12% discount to our quantitative fair value estimate of $99.09 per share, which is reinforced by this estimate's low uncertainty rating.
The firm's solid growth strengthens our estimated fair value. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's EPS 5-year growth of 13.3% sits in the top 40% compared with global peers. The robust five-year track record of EPS growth is reason to be optimistic about the firm's shares. We believe this is a sign that shares could be cheap.
Conversely, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 1.1, a core component of valuation, sits in the top 50% compared with global peers. The market value of equity is low relative to the business' enterprise value, suggesting the company could be buried in debt if anything goes wrong. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
经济护城河
The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.
作者:Quantitative Equity Report
报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
美利医疗系统 讨论区 0 条评论